BioLife Solutions Ownership
| BLFS Stock | USD 25.06 0.00 0.00% |
Shares in Circulation | First Issued 1988-09-30 | Previous Quarter 46.2 M | Current Value 46.1 M | Avarage Shares Outstanding 9.7 M | Quarterly Volatility 13.4 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
BioLife |
BioLife Stock Ownership Analysis
About 98.0% of the company shares are held by institutions such as insurance companies. The book value of BioLife Solutions was currently reported as 7.44. The company has Price/Earnings (P/E) ratio of 173.59. BioLife Solutions recorded a loss per share of 0.25. The entity had not issued any dividends in recent years. The firm had 1:14 split on the 29th of January 2014. BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington. Biolife Solutions operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 432 people. For more info on BioLife Solutions please contact Michael Rice at 425 402 1400 or go to https://www.biolifesolutions.com.BioLife Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as BioLife Solutions is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading BioLife Solutions backward and forwards among themselves. BioLife Solutions' institutional investor refers to the entity that pools money to purchase BioLife Solutions' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ameriprise Financial Inc | 2024-12-31 | 839.1 K | Geode Capital Management, Llc | 2024-12-31 | 833.4 K | Palisade Capital Management Llc | 2024-12-31 | 833.1 K | Rockefeller Capital Management L.p. | 2024-12-31 | 821.8 K | Royce & Associates, Lp | 2024-12-31 | 777.3 K | Massachusetts Financial Services Company | 2024-12-31 | 762.9 K | Ing Investment Management Llc | 2024-12-31 | 682.6 K | Gagnon Securities Llc | 2024-12-31 | 567.2 K | Bank Of America Corp | 2024-12-31 | 541.1 K | Casdin Capital, Llc | 2024-12-31 | 8.7 M | Blackrock Inc | 2024-12-31 | 5.6 M |
BioLife Solutions Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific BioLife Solutions insiders, such as employees or executives, is commonly permitted as long as it does not rely on BioLife Solutions' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases BioLife Solutions insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
BioLife Solutions Outstanding Bonds
BioLife Solutions issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. BioLife Solutions uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most BioLife bonds can be classified according to their maturity, which is the date when BioLife Solutions has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BIOGEN INC 52 Corp BondUS09062XAD57 | View | |
| BIOGEN INC 405 Corp BondUS09062XAF06 | View | |
| BIOGEN INC Corp BondUS09062XAG88 | View | |
| BIOGEN INC Corp BondUS09062XAH61 | View | |
| BIIB 325 15 FEB 51 Corp BondUS09062XAK90 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
BioLife Solutions Corporate Filings
F4 | 20th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 3rd of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 10th of January 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for BioLife Stock Analysis
When running BioLife Solutions' price analysis, check to measure BioLife Solutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLife Solutions is operating at the current time. Most of BioLife Solutions' value examination focuses on studying past and present price action to predict the probability of BioLife Solutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLife Solutions' price. Additionally, you may evaluate how the addition of BioLife Solutions to your portfolios can decrease your overall portfolio volatility.